| AVI BioPharma announced presentations on the company's exon skipping therapy for Duchenne muscular dystrophy at the TREAT-NMD / NIH International Conference taking place Nov. 17-19 in Brussels, Belgium. At the conference, data from the company's clinical and preclinical programs were presented. An update on the company's ongoing systemic Phase 1b/2 trial of AVI-4658 was provided by Professor Francesco Muntoni, of the MDEX consortium in the UK, during an oral presentation and also summarized in a poster presentation. The most recent data from the ongoing Phase 1b/2 trial at two MDEX sites in the UK demonstrate that AVI-4658 was well tolerated by DMD patients in a dose escalation study that is now up to the sixth and final cohort. The maximum cumulative dose administered to date is 3132 mg and the maximum single dose is 900 mg with no adverse safety signals, in either case. :theflyonthewall.com |
Subscribe for More Information